Similarly, two groups recently found that expression of PD-L1 in IBC tumor samples correlated with higher stromal tumor-infiltrating lymphocytes (sTIL) that were highly enriched in CD20+ B cells, and their combined presence was associated with better response to neoadjuvant therapy [17, 22]. The gene discussed is CD274; the disease is inflammatory breast carcinoma.